Clinical Trial

Personalized Preventive Support for Cognitive Impairment in Non-Metastatic Breast Cancer (EFACog)

Study acronym: EFACog
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
EFACog is a single-center prospective cohort feasibility study conducted on a single group of patients to study the feasibility of a personalized support program by a nurse conducted over 9 months, using face-to-face and telephone interviews. The objective of this support program is to prevent the occurrence of post-chemotherapy cognitive impairment. After a pre-inclusion visit, patients with no pre-existing cognitive impairment will be included in the study and will receive a 9-month follow-up after the first course of chemotherapy. All follow-up visits (telephone or face-to-face) will be scheduled in conjunction with those taking place in the care setting.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-09-08; most recent amendment 2026-07-17.
Status change: Recruiting → Active, Not Recruiting 2025-11-21
Status change: Not Yet Recruiting → Recruiting 2024-08-01
Trial Details
NCT Number NCT05538000
Lead Sponsor Institut de Cancérologie de Lorraine
Conditions No Metastatic Breast Cancer
Enrollment 50 participants
Start Date 2024-08-01
Primary Completion 2026-08-20 (estimated)
Study Completion 2027-06-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-20